乳腺癌合并中枢神经系统转移患者的治疗策略：现状与未来前景。
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
机构信息
Developmental Therapeutics Program, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.
Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
出版信息
Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532.
Abstract
Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood–brain barrier with new compounds. This article reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.
摘要
乳腺癌是中枢神经系统（CNS）转移性疾病的第二大主要原因。近年来，对乳腺癌生物学的深入了解，使得一部分转移性乳腺癌患者的生存率得到了前所未有的提高。HER2 阳性（HER2+）或三阴性乳腺癌患者发生 CNS 转移的风险最高，尽管采用局部和全身治疗，但其预后通常较差。在乳腺癌 CNS 转移的发展治疗领域中，面临的挑战之一是提高我们对其生物学细微差别以及血脑屏障与新化合物相互作用的认识。本文综述了与乳腺癌脑转移的基础生物学相关的最新发现、迄今为止的临床进展，并为探索性治疗提出了合理的方法。
相似文献
1
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532.
2
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Crit Rev Oncol Hematol. 2010 Aug;75(2):110-21. doi: 10.1016/j.critrevonc.2009.11.003. Epub 2009 Dec 9.
3
Molecular and cellular mechanisms underlying brain metastasis of breast cancer.
Cancer Metastasis Rev. 2020 Sep;39(3):711-720. doi: 10.1007/s10555-020-09881-y.
4
Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.
Curr Treat Options Oncol. 2022 Oct;23(10):1457-1476. doi: 10.1007/s11864-022-01011-w. Epub 2022 Sep 22.
5
New target therapies for brain metastases from breast cancer.
Curr Cancer Drug Targets. 2012 Mar;12(3):210-7. doi: 10.2174/156800912799277548.
6
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5.
7
[Brain metastasis of breast tumors and blood brain barrier].
Bull Cancer. 2011 Apr;98(4):385-9. doi: 10.1684/bdc.2011.1336.
8
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 breast cancer metastasis.
Breast Cancer Res. 2019 Aug 13;21(1):94. doi: 10.1186/s13058-019-1177-1.
9
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2.
10
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Ann Oncol. 2013 Dec;24(12):2999-3004. doi: 10.1093/annonc/mdt348. Epub 2013 Sep 6.
引用本文的文献
1
Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions.
Sci Rep. 2025 Jul 2;15(1):22623. doi: 10.1038/s41598-025-06645-y.
2
Temporal Dynamics and Clinical Predictors of Brain Metastasis in Breast Cancer: A Two-Decade Cohort Analysis Toward Tailored CNS Screening.
Cancers (Basel). 2025 Mar 11;17(6):946. doi: 10.3390/cancers17060946.
3
Identification and validation of N -methylguanosine-associated gene NCBP1 as prognostic and immune-associated biomarkers in breast cancer patients.
J Cell Mol Med. 2024 Jan;28(2):e18067. doi: 10.1111/jcmm.18067. Epub 2023 Dec 10.
4
Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases.
Breast Cancer (Dove Med Press). 2023 Nov 17;15:841-853. doi: 10.2147/BCTT.S440427. eCollection 2023.
5
Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
Front Oncol. 2023 Jun 16;13:1105474. doi: 10.3389/fonc.2023.1105474. eCollection 2023.
6
Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis.
Ther Adv Med Oncol. 2023 Apr 3;15:17588359231165976. doi: 10.1177/17588359231165976. eCollection 2023.
7
Systemic treatments for breast cancer brain metastasis.
Front Oncol. 2023 Jan 6;12:1086821. doi: 10.3389/fonc.2022.1086821. eCollection 2022.
8
Efficacy and safety of pyrotinib and radiotherapy . pyrotinib-based therapy in patients with HER2 breast cancer with brain metastasis: a retrospective cohort study.
Ann Transl Med. 2022 Nov;10(22):1228. doi: 10.21037/atm-22-5352.
9
Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):952-972. doi: 10.1080/14756366.2022.2053524.
10
Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.
Am J Cancer Res. 2022 Feb 15;12(2):549-561. eCollection 2022.
本文引用的文献
1
Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.
Clin Cancer Res. 2016 Dec 15;22(24):6078-6087. doi: 10.1158/1078-0432.CCR-16-1327. Epub 2016 Aug 12.
2
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.
3
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2.
4
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Breast Cancer Res. 2016 Apr 27;18(1):43. doi: 10.1186/s13058-016-0702-8.
5
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.
6
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.
7
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.
8
Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
Br J Cancer. 2016 Mar 29;114(7):793-800. doi: 10.1038/bjc.2016.34. Epub 2016 Feb 23.
9
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.
10
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
Zotero 插件